Amimax C Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Amikacin should be used with extreme caution in dogs, in which hearing acuity is required for functioning, such as seeing eye, hearing ear or military patrol, as the auditory and vestibular impairment tends not to be reversible.6
Aminoglycosides, including amikacin, are not indicated in uncomplicated episodes of cystitis unless causative agents are susceptible to them and are not susceptible to antibiotics having less potential for toxicity.
Early signs of ototoxicity can include ataxia, nausea and vomiting. Auditory and vestibular impairment may be reversible in the very early stages, but if treatment is continued, the conditions will become irreversible.6
Federal law restricts this drug to use by or on the order of a licensed veterinarian
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
AmiMax™ C Injection (amikacin sulfate) is indicated for the treatment of the following conditions in dogs:
Genitourinary tract infections (cystitis) caused by susceptible strains of Escherichia coli and Proteus sp.
Skin and soft tissue infections caused by susceptible strains of Pseudomonas sp and Escherichia coli.
While nearly all strains of Escherichia coli, Pseudomonas sp, and Proteus sp, including those that are resistant to gentamicin, kanamycin or other animoglycosides, are susceptible to amikacin at levels achieved following treatment, it is recommended that the invading organism be cultured and its susceptibility demonstrated as a guide to therapy. Amikacin susceptibility discs, 30 mcg, should be used for determining in vitro susceptibility.
There is currently no drug history available for this drug.
Amikacin sulfate is a semi-synthetic aminoglycoside antibiotic derived from kanamycin. It is C22H43N5O13•2H2SO4, D-streptamine, 0-3-amino-3-deoxy-α-D-glucopyranosyl-(1→6)-0-[6-amino-6-deoxy-α - D - g l u c o p y r a n o s y l - ( 1 → 4 ) ] -N1-(4-amino-2-hydroxy-1-oxobutyl)-2- deoxy-, (S)-, sulfate (1:2)(salt).
The dosage form supplied is a sterile, colorless to straw-colored solution containing, in addition to amikacin sulfate, 2.5% sodium citrate, pH adjusted with sulfuric acid, 0.66% sodium bisulfite added, and 0.1 mg benzethonium chloride per mL as a preservative.